Adjuvant Technology Articles & Analysis
3 news found
Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 Strong financial position supports investment in long-term growth drivers including pipeline expansion Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022 ...
The delivery platform, a liposome-based vaccine adjuvant, leverages technology that POP BIO has licensed from the State University of New York Research Foundation (SUNY-RF). A vaccine utilizing the POP BIO technology, EuCorVac-19, is currently in Phase II clinical studies through an ongoing collaboration and licensing arrangement between POP BIO ...
Preclinical research demonstrated that BlueWillow’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein resulted in an extremely high neutralizing antibody response, as well as a superior immunoglobulin A (IgA) response in both serum and lung secretions (BAL) samples in mice compared to intramuscular injection of S-2P adjuvanted with ...